You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK)與中生製藥(01177.HK)共研產品發布最新研究結果
阿思達克 01-20 08:22
康方生物(09926.HK)公布,公司與中國生物製藥(01177.HK)共同開發的抗PD-1單抗藥物派安普利(安尼可)(研發代號:AK105)聯合安羅替尼一線治療晚期肝癌(HCC)的最新研究在2021年國際胃腸道癌症研討會上發佈。

研究認為,派安普利聯合安羅替尼組合安全耐受,作為晚期HCC患者的一線治療表現出令人鼓舞的抗腫瘤活性。同時,研究結果支持探索更高劑量的安羅替尼與派安普利聯合,派安普利聯合安羅替尼(10毫克,連續服藥兩周,停藥一周)一線治療晚期HCC的III期臨床試驗(NCT04344158)正在進行中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account